Eli Lilly and Company (NYSE:LLY) Shares Sold by Sierra Capital LLC

Sierra Capital LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 23.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 247 shares of the company’s stock after selling 76 shares during the quarter. Sierra Capital LLC’s holdings in Eli Lilly and Company were worth $204,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. May Hill Capital LLC raised its holdings in Eli Lilly and Company by 1.3% in the 1st quarter. May Hill Capital LLC now owns 1,582 shares of the company’s stock worth $1,307,000 after purchasing an additional 21 shares during the period. Brown Advisory Inc. increased its stake in Eli Lilly and Company by 1.1% during the 1st quarter. Brown Advisory Inc. now owns 107,981 shares of the company’s stock worth $89,182,000 after buying an additional 1,125 shares in the last quarter. Consolidated Capital Management LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth approximately $6,338,000. Ninety One SA PTY Ltd grew its position in shares of Eli Lilly and Company by 118.1% in the first quarter. Ninety One SA PTY Ltd now owns 628 shares of the company’s stock valued at $506,000 after purchasing an additional 340 shares in the last quarter. Finally, Ninety One UK Ltd grew its position in shares of Eli Lilly and Company by 8.3% in the first quarter. Ninety One UK Ltd now owns 306,738 shares of the company’s stock valued at $253,338,000 after purchasing an additional 23,637 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $772.82 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $732.43 billion, a P/E ratio of 62.88, a PEG ratio of 1.14 and a beta of 0.40. The business has a 50 day simple moving average of $771.52 and a 200-day simple moving average of $800.30. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.58 earnings per share. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on LLY shares. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price objective for the company. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.